Peptide marketing is the question every clinic, compounder and distributor is asking this quarter. The status answer now sits in two places: an FDA page and an HHS policy dated October 30, 2026. The claim rules have not changed. This post gives you seven rules for what you may say about peptides, where to check a substance’s status, and how to keep a page honest each month.
TLDR: Peptide marketing starts with one question: is this substance an approved drug, a compounded drug, or neither. On October 30, 2026, HHS published an interim policy that lets licensed 503A pharmacies compound six peptides under ten conditions. It is not FDA approval. Only those six can carry an availability line, and only with every control in place. Every other peptide gets education and a dated status line. No peptide gets a benefit or outcome claim. Read on for the seven rules, the mistakes we see most, and a short monthly check.
Important Note
This article is for educational purposes only and does not constitute legal, medical, or regulatory advice. Marketing strategies discussed should be reviewed by qualified legal counsel before implementation, particularly regarding FDA, FTC, and state-specific advertising regulations. Regen Portal is a marketing and consulting company, not a law firm. Nothing here implies FDA approval of any product or any use. Most cell, tissue and exosome products marketed to patients are not FDA approved, and the few cell-based products the FDA has approved are approved only for specific labeled indications. Nothing here promises a marketing or business outcome. Regulations change and enforcement varies by state. Confirm current requirements with qualified legal and compliance counsel before you act on anything you read here.
Everyone is asking about peptides this quarter. Clinics, compounders and distributors alike. It is the newest fad, pushed by GLP-1 demand and by influencers on TikTok selling what I call hopeium. The calls all sound the same. What can we say, and where do we check?
The answer has two parts. The claim rules are old and stable. The product status is not. It lives on an FDA page with a date at the bottom and, since October 30, 2026, in an HHS policy that covers six peptides. This post covers both: seven rules for peptide marketing, the mistakes we see, and a monthly routine that keeps a page current.
Why Peptide Marketing Is Harder Than It Looks
Peptide marketing is hard because one word covers three different legal things. A peptide can be the active ingredient in an approved drug. It can be a bulk substance a compounder uses under Section 503A of the Food, Drug, and Cosmetic Act. Or it can be neither, sold in a vial with a label that says it is for research.
Each bucket allows a different set of words. A page that mixes them borrows the strongest claim from the first bucket and hangs it on the third. That is where the trouble starts.
The second problem is evidence. When we ask a practice or a vendor what stands behind a peptide sentence, the answer is usually vendor materials. Sometimes a certificate of analysis or a public trial. Often not much at all. The influencer who made the claim famous has no file. The clinic that copied it has none either.
So the work has two halves. Sort the substance into the right bucket, then say only what that bucket allows. The sorting starts on one FDA page.
The FDA 503A Page Is the Reference, and It Changes
The FDA’s 503A bulk drug substances page is where a compounded peptide’s status lives. When I checked it again on November 3, 2026, the 503A page showed a content date of May 14, 2026. It does not mention the HHS policy for peptides, so you need both sources. If you are reading this later, open them before you trust a word of this post.
Section 503A covers drugs compounded by a licensed pharmacist or physician for an individual patient. A bulk drug substance may be used in 503A compounding if it meets one of three conditions, among others. It complies with an applicable USP or NF monograph. It is a component of an FDA-approved drug. Or it appears on the FDA’s 503A bulks list. Counsel confirms the rest. Many nominated substances meet none of the three yet.
For those, the FDA 503A bulk drug substances page describes an interim policy with three categories. Two terms first. A nominated substance is one someone asked the FDA to add to the list. Enforcement discretion means the FDA has said it does not intend to act while set conditions are met.
| Category | What the FDA page says | What it means for a page |
|---|---|---|
| Category 1 | Nominated with enough data to review, may be eligible for the list, and not on any other list | The FDA does not intend to act against a compounder using it, if the guidance conditions are met |
| Category 2 | Nominated with enough data, but the FDA has found significant safety risks pending further review | The FDA says it would consider action under its general enforcement policies |
| Category 3 | Nominated with too little data for the FDA to review | Not covered by the Category 1 policy |
Those three rows tell a compounder what it may use. They do not tell a marketing page what it may say. For peptides, the HHS policy below now draws that line.
Two more things on the page matter. First, the FDA page notes guidance saying the agency does not intend to place substances nominated on or after January 7, 2025 into these categories. A newly nominated peptide may sit in no bucket at all. Second, the page itself names no substances. The names sit in a linked list the FDA updates.
I am not repeating any peptide’s category here. The list can change between the day I write and the day you read. Open the page, open the list, and write down the date shown. That habit is Rule 2, and the rest follow it.
One dated history is worth stating, because clinics keep getting it wrong. On April 22, 2026, the FDA took twelve well-known peptides off Category 2 after their nominations were withdrawn. An FDA advisory committee reviewed seven of them on July 23 and 24, 2026, and recommended six. Off Category 2 was never the same as cleared to compound. Then HHS acted.
The October 30, 2026 HHS Policy for Six Peptides
On October 30, 2026, HHS published an interim policy for six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. A licensed 503A pharmacy may compound them, one at a time, on an individual prescription, when ten conditions are met. It is not FDA approval, it does not put them on the 503A bulks list, and HHS may revisit it. Every other peptide stays outside it.
The ten conditions are specific. They include a single ingredient, an FDA-registered original maker named on the certificate of analysis, a route the policy allows, a “Not for resale” label and adverse event reporting. The pharmacy confirms them, not the clinic’s marketing team. The FDA still has not evaluated any of the six for safety or effectiveness.
The policy also says nothing about advertising. It lets a pharmacy compound. It does not give a page permission to sell. Peptides clinics ask about often, such as CJC-1295, ipamorelin, thymosin alpha-1, AOD-9604 and Melanotan II, are not covered at all.
The Seven Rules of Peptide Marketing
The seven rules take a page from what everyone says to what this practice can defend. Run them on every page, caption, deck and rep script that mentions a peptide.
Rule 1: Sort the Substance Before You Write
Before a word is written, sort the substance. Approved drug, compounded drug, or neither. For marketing, an unapproved peptide sits in the compounded bucket only if it is one of the six in the HHS policy, made under its ten conditions. The answer sets the ceiling on every line that follows. If nobody in the practice can answer in one sentence, the page is not ready.
For an approved drug, the approved labeling sets the limits. For one of the six compounded peptides, the HHS policy, the 503A rules and state pharmacy law set them. For the third bucket there is no ceiling to find, because there is no lawful clinical product to market. Counsel decides which bucket fits the practice’s own supply.
Rule 2: Date Every Status Statement
Every sentence about status carries the date you read it. “As of the FDA page dated May 14, 2026, and the HHS policy of October 30, 2026″ is the form. Add the day you read them. A status sentence without a date is a claim about today, and today keeps moving.
This sounds fussy until the list changes. A practice that dated its page can show what it knew and when. A practice that did not is defending a line that may have been true once.
Rule 3: No Disease or Outcome Claims for Compounded or Unapproved Peptides
No compounded or unapproved peptide gets a disease claim or an outcome claim on any page. The FTC’s Health Products Compliance Guidance asks for competent and reliable scientific evidence behind health claims. For health benefit claims, it says randomized, controlled human clinical trials are generally what experts would require. Vendor sheets and influencer clips are not that.
The FDA side is simpler. A product marketed to treat a disease is being marketed as a drug. The FDA’s consumer alert on regenerative medicine products covers stem cells and exosomes, not peptides. But its logic is the one a reviewer applies to any unapproved product. So “supports recovery,” “heals tissue” and “reverses aging” are all do-not-use lines for a compounded peptide. That holds for the six HHS peptides too. The policy lets a pharmacy compound them. It does not allow a single benefit claim.
Rule 4: A Research Label Does Not License a Clinic
A vial labeled “for research use only” or “not for human use” is not a clinical product. A clinic may not market it as one. The label states the seller’s intent. It does not change what happens when a practice puts the product on a page next to a booking button.
Intended use follows the marketing, not the sticker. Counsel decides the practice’s own exposure, but the peptide marketing rule is plain. If it is labeled for research, it does not belong on a patient-facing page at all. The FDA also sent warning letters to sellers of research-use-only peptides on March 31 and August 24, 2026. Do not link to those sellers or repeat their claims.
Rule 5: Only Six Peptides Get an Availability Line
Only six peptides may carry an availability line: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Even for those six, the line runs only when every control below is in place. Miss one and the line comes down.
- Written confirmation from the 503A pharmacy that all ten HHS conditions are met, kept on file.
- The compounded peptide notice, word for word with the peptide’s name filled in, right next to the line.
- No benefit, recovery or outcome claim anywhere on the page.
- One peptide per line. No stacks or blends.
- No paid ads for it, and no link to a research-use-only seller.
- Counsel confirms the state board’s position before the line goes live.
- A date on the page, with the date of the HHS policy.
Never call any of the six “FDA approved,” “legal now” or “on the bulks list.” None of that is true.
Every other peptide gets education and a dated status line, nothing more. That covers peptides in Category 2, any peptide nominated on or after January 7, 2025, and any peptide taken off Category 2 that is not one of the six. “Now offering” and “ask about our” are availability claims, and they read as such. Counsel confirms.
Rule 6: Educate, Do Not Sell
Education about peptides is allowed. Sales language is not, for anything in the compounded or research-labeled buckets. The difference is not the topic. It is the net impression, which the FTC guidance judges from the ad as a whole.
A page that explains what a peptide is, how the FDA sorts bulk substances, and what a consult covers is education. A page that names a peptide, lists benefits, and ends with a booking link is a sale. It stays a sale no matter how many times it says “educational.” Our traffic light guide to what clinics can and cannot say sorts these lines fast.
Rule 7: Review the Page Monthly
Put the FDA 503A page and the HHS policy on a monthly calendar. Open both, check the dates, open the list, and compare them to every status line you have live. If a category moved, or HHS changed or withdrew its policy, update the page the same day and record the change.
That review takes minutes when the page is dated. It is the one rule that keeps the other six true, because status is the only part of peptide marketing that moves.
Those are the rules. Here are the ways practices break them without meaning to.
Common Peptide Marketing Mistakes We See
The most common peptide marketing mistake is drift. Almost none of the exposure we find in clinic marketing was put there on purpose. It drifts one word at a time, from “being studied for” to “helps” to “treats,” usually in a subheading nobody thinks of as copy. Peptide pages drift faster than most, because the influencer version starts at “treats.”
The second mistake is copying the influencer. A TikTok claim has no file behind it. A practice that repeats it owns the claim with none of the cover. The FDA warning letters we read describe unapproved products by claim type, and the claims usually started somewhere else. We break down how FDA warning letters work in a separate guide.
Third, borrowing the approved drug’s language. A compounded product is not the approved drug, even when the active ingredient shares a name. Approved labeling belongs to the approved product. A compounded page that lifts it is making a claim it cannot hold.
Fourth, trusting the vendor deck. When a product company hands us a deck to review, we flag three things first. Claims that are not compliant, wording too complex for the buyer, and weak graphics. A rep’s slide does not become evidence when a clinic pastes it.
Fifth, hiding the sale inside “education.” A page can be one word away from a letter even when the header says educational. Reviewers read the whole page, buttons included.
Here is what all seven rules look like on one page.
One Practice, One Peptide Page, and the Monthly Check
Picture a wellness practice in a mid-sized city that added peptides last spring. The page names three peptides, calls them “next-generation recovery therapy,” lists benefits under each, and ends with a booking button. Two of the three came in vials that read “for research use only.” Do not use that page. Here is the rebuild.
Rule 1. The practice sorts the three. One is BPC-157, compounded by a licensed 503A pharmacy on individual prescriptions. Two are research-labeled products, and they come off the page under Rule 4. Counsel confirms the practice’s position on the compounded one.
Rule 2. The remaining status line gets its dates: the FDA page’s content date and the HHS policy date, both read that morning.
Rule 3. Every benefit line comes off. “Recovery therapy” comes off. The page now says what a peptide is and what the HHS policy says about this substance, with the date. No outcome. No condition.
Rules 5 and 6. BPC-157 is one of the six in the HHS policy, so one plain availability line is possible. First, the practice gets written confirmation from the pharmacy that all ten conditions are met. Then counsel confirms the state board’s position. Here is the line. “We prescribe compounded BPC-157 from a licensed 503A pharmacy on an individual prescription under the October 2026 HHS policy.” The notice sits right next to it, word for word:
BPC-157 is a compounded drug prepared by a licensed 503A compounding pharmacy based on an individual patient prescription, under an interim enforcement discretion policy issued by the U.S. Department of Health and Human Services in October 2026. Compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing. No FDA-approved product containing BPC-157 exists, and FDA has not evaluated BPC-157 for any use. The policy may be withdrawn at any time.
The page carries no benefit claim, no stack and the date. The peptide gets no paid ads. The booking link sits after the education, never beside the availability line. Had the compounded peptide been anything outside the six, such as CJC-1295, the page would get a status explainer and nothing more. Counsel signs off on the final page.
Rule 7. The practice manager adds a monthly reminder. First Monday: open the FDA page and the HHS policy, check both dates, compare the list, record either way.
Counsel decides whether the rebuilt page is right for that practice in that state. The seven rules got it to the point where counsel had something clean to decide. Getting a page to that point is the job our regen marketing compliance support is built for.
Frequently Asked Questions
What Is Peptide Marketing Allowed to Say in 2026?
Peptide marketing may educate. For an FDA-approved peptide drug, the approved labeling sets the limits. For the six peptides in the October 30, 2026 HHS policy, one dated availability line is possible. It needs the pharmacy’s written confirmation of all ten conditions and the compounded peptide notice beside the line. It also needs no benefit claim, no stack, no paid ads, and counsel confirming the state board’s position. Every other peptide gets education and a dated status line, nothing more. No compounded or unapproved peptide gets a disease or outcome claim. Counsel confirms the fit for each practice and state.
Where Do I Check a Peptide’s Compounding Status?
Two places. First, the FDA’s 503A bulk drug substances page and the list it links to. The page describes three categories for nominated substances and shows a content date at the bottom. When I checked on November 3, 2026, the page date was still May 14, 2026. Second, the HHS policy of October 30, 2026, which covers six peptides only. Record both dates before you write a status line.
Does a “Research Use Only” Label Protect the Clinic?
No. The label states the seller’s intent. It does not make a product lawful to market for patient use, and a page that promotes a research-labeled product to patients says the opposite. Keep research-labeled products off patient-facing pages. Counsel decides the exposure on any product already in use.
Can a Clinic Use the Approved Drug’s Claims for a Compounded Version?
No. Approved labeling belongs to the approved product. A compounded product is a different product, even when the active ingredient shares a name. Any claim on a compounded peptide page must stand on its own evidence, which is the FTC standard.
Is Peptide Marketing Different From Stem Cell Marketing?
The claim rules are the same. The status source is different. Stem cell and exosome status runs through the FDA’s tissue rules and its consumer alert, which we covered in what you can say about stem cells. Peptide status runs through drug compounding rules, the 503A page and the HHS policy. Same discipline, different bookmark.
Key Takeaways
- In peptide marketing, a substance is an approved drug, a compounded product from a bulk substance, or neither, and each bucket allows different words.
- Status lives in two places. The FDA’s 503A page still showed a content date of May 14, 2026 on November 3, 2026. The HHS policy of October 30, 2026 covers six peptides and is not FDA approval.
- No disease or outcome claim attaches to any compounded or unapproved peptide, and approved drug claims do not carry over.
- A research-use label does not license a clinic to market a product. Only the six HHS peptides may carry an availability line, with every control and the notice beside it. Every other peptide gets education and status only.
- Education is allowed, sales language is not, and the whole page’s net impression is what gets judged.
- Review the FDA page and the HHS policy monthly, date every status line, and record each check.
Your Next Step
Most peptide pages we see were written from a supplier deck and an influencer clip, with no date and no file. Regen Portal builds the claims inventory first, sorts each substance into its bucket, and rewrites the page down to what the practice can defend. The claims substantiation routine we published this month runs underneath all of it.
PS: Send us one peptide service page or one product one-pager and we will run a free compliance audit on it.
Email: hello@regenportal.com
YouTube: Subscribe to the channel
About Regen Portal
Regen Portal is a marketing and consulting company built for the regenerative medicine industry. We handle practice consulting, marketing compliance, search engine optimization, content creation, social media management, paid advertising, website development, branding, and AI and ops consulting for clinics, manufacturers, distributors, and independent providers. For more on me and how we work, visit Regen Portal and contact us.
About the Author
Oscar Tellez is the founder of Regen Portal, a marketing and consulting company built for the regenerative medicine industry. He has been in this industry since 2015. He started in medical sales and has worked with PRP since 2016. He has reached hundreds of practices and over 200 doctors through sales, teaching and marketing. He holds a B.S. in Exercise Science and Health Promotion from Florida Atlantic University.
